[HTML][HTML] Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)?
JP Gisbert, M Chaparro - Journal of Clinical Medicine, 2021 - mdpi.com
Background: About a third of patients with inflammatory bowel disease do not respond to
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
JP Gisbert, M Chaparro - Journal of Clinical Medicine, 2021 - search.ebscohost.com
Background: About a third of patients with inflammatory bowel disease do not respond to
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
JP Gisbert, M Chaparro - Journal of Clinical Medicine, 2021 - search.proquest.com
Background: About a third of patients with inflammatory bowel disease do not respond to
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
[HTML][HTML] Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
JP Gisbert, M Chaparro - Journal of Clinical Medicine, 2021 - ncbi.nlm.nih.gov
Background: About a third of patients with inflammatory bowel disease do not respond to
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
JP Gisbert, M Chaparro - Journal of Clinical Medicine, 2021 - europepmc.org
Background: About a third of patients with inflammatory bowel disease do not respond to
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …
Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
JP Gisbert, M Chaparro - Journal of clinical medicine, 2021 - pubmed.ncbi.nlm.nih.gov
Background About a third of patients with inflammatory bowel disease do not respond to anti-
tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim To review the current …
tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim To review the current …